| |
| HCC |Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
| Abstract Details |
 |
|
| |
| |
| |
|
|
| |
Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA |
|
|
|
|
| |
Future Oncol. 2021 Jul;17(21):2759-2768. doi: 10.2217/fon-2021-0242. Epub 2021 Apr 9.
Amit G Singal 1, Saurabh P Nagar 2, Abby Hitchens 2, Keith L Davis 2, Shrividya Iyer 3
|
| |
|
|
| |
Author information
- 1Division of Digestive & Liver Disease, UT Southwestern Medical Center, Dallas, TX 75390, USA.
- 2Department of Health Economics, RTI Health Solutions, Research Triangle Park, NC 27709, USA.
- 3Global Real World Evidence & US HEOR, Eisai, Inc., Woodcliff Lake, NJ 07677, USA.
Abstract
Aim: This study evaluated the effectiveness of lenvatinib monotherapy for first-line treatment of unresectable hepatocellular carcinoma (uHCC) in a real-world setting. Materials & methods: This retrospective cohort study included patients who initiated lenvatinib monotherapy as first-line treatment for uHCC (n = 233). Clinical outcomes included provider-reported best response, progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated using Kaplan-Meier methods. Results: Most patients (67.8%) were male. A total of 44.6% had Child-Pugh A and 39.1% had Child-Pugh B. Dose reductions were reported in 9%. Median PFS and OS were not reached. At 6 and 12 months, landmark PFS were 85.1 and 64.9%, respectively; landmark OS were 91.8 and 72.6%, respectively. Conclusion: These results affirm the clinical effectiveness of first-line lenvatinib monotherapy in uHCC.
|
|
|
|
| |
| |
|
| |
|
|
|
|
|
